Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02923778 · ClinicalTrials.gov registry record · Phase 2
Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery
A Phase 2 study of Soft Tissue Sarcoma and Leiomyosarcoma, sponsored by National Cancer Institute (NCI).
- Active
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 17
- Study locations
NCT02923778: Active Phase 2 study of Soft Tissue Sarcoma and Leiomyosarcoma, sponsored by National Cancer Institute (NCI).
NCT02923778 is a Phase 2 study of Soft Tissue Sarcoma and Leiomyosarcoma that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 40 participants, below the 78-participant average among 55 other Soft Tissue Sarcoma trials with a reported enrollment target (49% lower). The trial reports 17 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02923778, a Phase 2 study of Soft Tissue Sarcoma and Leiomyosarcoma, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 17
- Study locations
Study Summary
This phase II trial studies the side effects of talimogene laherparepvec and radiation therapy and to see how well they work in treating patients with newly diagnosed soft tissue sarcoma that can be removed by surgery (resectable). Biological therapies, such as talimogene laherparepvec, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop cancer cells from growing. Radiation therapy uses high energy x-rays, photons. electrons, or protons to kill tumor cells and shrink tumors. Giving talimogene laherparepvec and radiation therapy may work better in treating patients with soft tissue sarcoma.
Primary Outcome
Will be defined as \>= 95% of tumor having necrosis. The estimated pathologic CR rate and a 95% confidence interval will be reported.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Magnetic Resonance Imaging
- PROCEDURE Biopsy Procedure
- RADIATION Radiation Therapy
- BIOLOGICAL Talimogene Laherparepvec
Study Locations (17)
Florida
- Mayo Clinic in Florida - Jacksonville
- University of Miami Miller School of Medicine-Sylvester Cancer Center - Miami
- Moffitt Cancer Center - Tampa
Missouri
- Siteman Cancer Center at West County Hospital - Creve Coeur
- Washington University School of Medicine - St Louis
- Siteman Cancer Center-South County - St Louis
California
- City of Hope Comprehensive Cancer Center - Duarte
- UC Irvine Health/Chao Family Comprehensive Cancer Center - Orange
Arizona
- Mayo Clinic Hospital in Arizona - Phoenix
Minnesota
- Mayo Clinic in Rochester - Rochester
New Hampshire
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center - Lebanon
New York
- Laura and Isaac Perlmutter Cancer Center at NYU Langone - New York
Ohio
- Ohio State University Comprehensive Cancer Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2019-12-31 |
| Est. Completion | 2026-12-29 |
| Phase | Phase 2 |
What the registry record for NCT02923778 still lists
NCT02923778 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 78-participant average among 55 other Soft Tissue Sarcoma trials with a reported enrollment target (49% lower).
The record links to 9 conditions, with Soft Tissue Sarcoma appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT02923778 lists 17 locations in 12 states (Florida, Missouri, California).
Frequently Asked Questions
What is clinical trial NCT02923778 about?
NCT02923778 is a clinical study titled "Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery". This phase II trial studies the side effects of talimogene laherparepvec and radiation therapy and to see how well they work in treating patients with newly diagnosed soft tissue sarcoma that can be removed by surgery (resectable). Biological therapies, such as talimogene laherparepvec, use substanc...
What is the current status of trial NCT02923778?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2019-12-31. Estimated completion is 2026-12-29.
What conditions does trial NCT02923778 study?
This clinical trial studies the following conditions: Soft Tissue Sarcoma, Leiomyosarcoma, Liposarcoma, Undifferentiated Pleomorphic Sarcoma, Sarcoma G2.
What interventions are being tested in trial NCT02923778?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Magnetic Resonance Imaging (PROCEDURE), Biopsy Procedure (PROCEDURE), Radiation Therapy (RADIATION), Talimogene Laherparepvec (BIOLOGICAL).
Who is sponsoring clinical trial NCT02923778?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02923778 being conducted?
This trial has 17 study locations across Arizona, California, Florida, Minnesota, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Soft Tissue Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02923778's enrollment target sits among peer trials
40 27th of 55 higher than 24 of 55 other Soft Tissue Sarcoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Soft Tissue Sarcoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Clinical Study to Investigate the Efficacy of Intratumoral Tigilanol Tiglate in Soft Tissue Sarcoma
RECRUITING · Phase 2
-
Preoperative 5-Day Radiotherapy for Soft Tissue Sarcoma
RECRUITING · Phase 2
-
Hypofractionated vs Conventional Fractionated RT in Soft Tissue Sarcomas
RECRUITING · Phase 2
-
SATURN-STS: Phase II Study of Neoadjuvant Atezolizumab With Doxorubicin, Concurrent Atezolizumab With Pre-operative Radiation Therapy and Adjuvant Atezolizumab in Patients With High-risk Surgically Resectable Extremity and Truncal Soft Tissue Sarcoma
RECRUITING · Phase 2
-
5-Day Preoperative Radiation for Soft Tissue Sarcoma
RECRUITING · Phase 2
-
Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI